Table 2.
Treatment characteristics
| Characteristics | n | (%) |
|---|---|---|
| Radiotherapy field | ||
| Whole pelvis and lower para-aortic lymphatics | 4 | 4.4 |
| Whole pelvis and entire para-aortic lymphatics | 86 | 95.6 |
| Chemotherapy | ||
| None | 44 | 48.9 |
| Concurrent chemotherapy | 46 | 51.1 |
| Weekly cisplatin or carboplatin | 24 | 26.6 |
| Cisplatin or carboplatin followed by 5-FU | 22 | 24.5 |
| Total dose to point A (Gy) | ||
| Median | 70.2 | |
| Range | (56–93) | |
| Interquartile range (75th and 25th percentiles) | 14.4 (80.4,66) | |
| Total dose to para-aortic lymphatics | ||
| Median | 50.4 | |
| Range | (45–60.4) | |
| Interquartile range (75th and 25th percentiles) | 3.6 (54, 50.4) | |
| Radiotherapy duration (days) | ||
| Median | 69 | |
| Range | (43–182) | |
| Interquartile range (75th and 25th percentiles) | 20 (80, 60) |